Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY:ASX)

10.36 UNCHANGED
Official Closing Price Updated: 7:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ASE Technology Holding Co., Ltd. American Depositary Shares (each representing

< Previous 1 2 3 4 5 6 Next >
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Life360 Enhances Ad Platform With Launch of Place Ads and Uplift, Redefining Real-World Targeting and Measurement
Company introduces breakthrough ad tools that deliver brand messages based on real-world behavior and prove in-store impact with deterministic measurement 
From Life360, Inc.
Via GlobeNewswire
Life360 Announces Closing of Upsized $320 Million Offering of 0.00% Convertible Senior Notes
From Life360, Inc.
Via GlobeNewswire
Life360 Announces Pricing of Upsized Convertible Senior Notes Offering
From Life360, Inc.
Via GlobeNewswire
Life360 Proposes Convertible Senior Notes Offering
From Life360, Inc.
Via GlobeNewswire
ASE Announces FOCoS-Bridge With TSV; Latest Package Technology Reduces Power Loss by 3x for Next-Generation AI and HPC Applications
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
Life360 Reports Record Q1 2025 Results
From Life360, Inc.
Via GlobeNewswire
Alterity Therapeutics Prominently Featured at the International MSA Congress
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
ATH434 Phase 2 Data to be Presented at Opening Plenary Session 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
ASE Technology Holding Co Honors Outstanding Suppliers of 2024
From ASE Technology Holding Co., Ltd.
Via Business Wire
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
ASE Demonstrates CPO that Improves Energy Efficiency for AI applications
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Oil & Gas Virtual Investor Conference Agenda Announced for March 27th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life360 Adds a Touch of Kawaii With Tile X Hello Kitty®, a Limited-Edition Collection in Partnership With Sanrio
Hello Kitty® Adds Her Supercute Charm to a Specially Designed Lineup of Bluetooth Trackers, Tile Mate and Tile Slim, Available Starting March 20 
From Life360, Inc.
Via GlobeNewswire
Life360 Appoints Former Amazon Cybersecurity Lead Vari Bindra as Chief Information Security Officer
Newly-created role underscores company’s commitment to safeguarding the digital well-being of millions of families worldwide 
From Life360, Inc.
Via GlobeNewswire
Baker Hughes and Woodside Energy Announce Collaboration Framework to Develop Small-Scale Decarbonization Solution Utilizing Net Power Platform
From Baker Hughes
Via GlobeNewswire
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Life360 Reports Record Q4 and FY 2024 Results
From Life360, Inc.
Via GlobeNewswire
Life360 Enhances Advertising Capabilities with Strategic Acquisition of Fantix’s AdTech AI Platform
AI Data Science platform will empower smarter, targeted advertising solutions while preserving privacy 
From Life360, Inc.
Via GlobeNewswire
ASE Expands its Chip Packaging and Testing Facility to Enable Next-Gen Applications
From Advanced Semiconductor Engineering, Inc.
Via Business Wire
Alterity Therapeutics Raises A$40.0 million in Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Life360 to Announce Q4 and Full Year 2024 Financial Results on February 27, 2025
From Life360, Inc.
Via GlobeNewswire
Dotz Nano to Present at the Small Cap Growth Virtual Investor Conference February 6th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.